Karen Wagner, a General Partner at Ysios Capital, invests primarily in biotech and therapeutic companies across seed. See sector focus and contact routes.
Karen Wagner, a General Partner at Ysios Capital, invests primarily in biotech and therapeutic companies across seed to development stages, with Series A as the firm’s sweet spot and check sizes typically ranging from $1M to $7.5M for her personal sweet spot, though she has participated in larger rounds up to $64M. Her portfolio includes notable companies such as Minoryx Therapeutics, AELIX Therapeutics, Kala Pharmaceuticals, Cytoki Pharma, and Galecto, and she serves on or chairs their boards. Wagner’s distinctive thesis is modality-agnostic investment in both single assets and platforms with proprietary pipelines, targeting multiple therapeutic areas without bias toward a specific drug type.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Zurich.
Investors like Karen Wagner · Full investor directory · Investor access · Company funding database